{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T09:03:27Z","timestamp":1781082207850,"version":"3.54.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Region Stockholm","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut and Alice Wallenberg Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031813","name":"Nordstjernan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031813","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ebiom.2026.106279","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T19:15:49Z","timestamp":1778267749000},"page":"106279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Three-year follow-up of the COVAXID trial: real-world assessment of SARS-CoV-2 mRNA vaccine immunogenicity in immunocompromised individuals highlights increasing roles of hybrid and passive immunity"],"prefix":"10.1016","volume":"128","author":[{"given":"Puran","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotta","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Mielke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"S\u00f6derdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"\u00d6sterborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.I. Edvard","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Vesterbacka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wullimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Cuapio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Akber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordana","family":"Bogdanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Muschiol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"\u00c5berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Lor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret S\u00e4llberg","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Ljungman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Buggert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo","family":"Aleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0908-7387","authenticated-orcid":false,"given":"Hans-Gustaf","family":"Ljunggren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ebiom.2026.106279_bib1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1186\/s13063-020-04352-9","article-title":"Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial","volume":"21","author":"Wang","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.ebiom.2026.106279_bib2","article-title":"Covid-19: WHO declares pandemic because of \"alarming levels\" of spread, severity, and inaction","volume":"368","author":"Mahase","year":"2020","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106279_bib3","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/cid\/ciaa863","article-title":"COVID-19 in immunocompromised hosts: what we know So far","volume":"72","author":"Fung","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"13","key":"10.1016\/j.ebiom.2026.106279_bib4","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1182\/bloodadvances.2024015260","article-title":"Outcomes of the COVID-19 pandemic in chronic lymphocytic leukemia: focus on the very early period and Omicron era","volume":"9","author":"Hedberg","year":"2025","journal-title":"Blood Adv"},{"issue":"15","key":"10.1016\/j.ebiom.2026.106279_bib5","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.ebiom.2026.106279_bib6","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2026.106279_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103705","article-title":"Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial","volume":"74","author":"Bergman","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ebiom.2026.106279_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104700","article-title":"Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID","volume":"94","author":"Chen","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ebiom.2026.106279_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105385","article-title":"Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID","volume":"109","author":"Chen","year":"2024","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106279_bib11","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2026.106279_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101505","article-title":"T cell immunity to SARS-CoV-2","volume":"55","author":"Niessl","year":"2021","journal-title":"Semin Immunol"},{"issue":"90","key":"10.1016\/j.ebiom.2026.106279_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adh0687","article-title":"SARS-CoV-2 vaccination enhances the effector qualities of spike-specific T cells induced by COVID-19","volume":"8","author":"Cai","year":"2023","journal-title":"Sci Immunol"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106279_bib14","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1007\/s10875-022-01283-9","article-title":"Neutralizing SARS-CoV-2 antibodies in commercial immunoglobulin products give patients with X-linked agammaglobulinemia limited passive immunity to the Omicron variant","volume":"42","author":"Lindahl","year":"2022","journal-title":"J Clin Immunol"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106279_bib15","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s10875-023-01486-8","article-title":"SARS-CoV-2 antibodies in commercial immunoglobulin products show markedly reduced cross-reactivities against Omicron variants","volume":"43","author":"Lindahl","year":"2023","journal-title":"J Clin Immunol"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106279_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29738","article-title":"Clinical efficacy of SARS-CoV-2 Omicron-neutralizing antibodies in immunoglobulin preparations for the treatment of agammaglobulinemia in patients with primary antibody deficiency","volume":"96","author":"Karbiener","year":"2024","journal-title":"J Med Virol"},{"issue":"9","key":"10.1016\/j.ebiom.2026.106279_bib17","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.immuni.2022.07.005","article-title":"Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination","volume":"55","author":"Gao","year":"2022","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106279_bib18","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.chom.2023.12.010","article-title":"Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant","volume":"32","author":"Muller","year":"2024","journal-title":"Cell Host Microbe"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106279_bib19","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/s41591-022-01700-x","article-title":"Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant","volume":"28","author":"Gao","year":"2022","journal-title":"Nat Med"},{"issue":"704","key":"10.1016\/j.ebiom.2026.106279_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg9452","article-title":"Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states","volume":"15","author":"Muller","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ebiom.2026.106279_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fbinf.2022.876380","article-title":"Bioinformatic and experimental analysis of T cell immune reactivity to SARS-CoV-2 and its variants","volume":"2","author":"Tarke","year":"2022","journal-title":"Front Bioinform"},{"issue":"7","key":"10.1016\/j.ebiom.2026.106279_bib22","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1038\/s41591-023-02414-4","article-title":"SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease","volume":"29","author":"Barnes","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106279_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-16402-0","article-title":"Kinetics of anti-nucleocapsid IgG response in COVID-19 immunocompetent convalescent patients","volume":"12","author":"Movsisyan","year":"2022","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.ebiom.2026.106279_bib24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41579-025-01185-8","article-title":"SARS-CoV-2 spike protein: structure, viral entry and variants","volume":"23","author":"Chen","year":"2025","journal-title":"Nat Rev Microbiol"},{"issue":"6572","key":"10.1016\/j.ebiom.2026.106279_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/science.abm0829","article-title":"mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern","volume":"374","author":"Goel","year":"2021","journal-title":"Science"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426001611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426001611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:40:46Z","timestamp":1781080846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396426001611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":24,"alternative-id":["S2352396426001611"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106279","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Three-year follow-up of the COVAXID trial: real-world assessment of SARS-CoV-2 mRNA vaccine immunogenicity in immunocompromised individuals highlights increasing roles of hybrid and passive immunity","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106279","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106279"}}